- Welcome
- Presentations
- Forum
- Blog
- YouTubule
- Resources
- Publications
- Guidelines
- Network
Nephrology Tools 
Nephrology Self Assessment Quiz 
Ask the Experts 
Nephrology Nutrition 
Polls 
Nephrology Journals 
Nephrology Books
Subscribe to blog
UKidney Blog
News and opinion from the world of Nephrology, brought to you by UKidney
Bloggers
Dr. Jordan Weinstein
Learning how to put in a PD catheter on Ukidney
Recent Posts
-
Treating microalbuminuria to reduce cardiovascular disease: an increasingly dangerous strategy
At the end of 2011, Novartis suspended the ALTITUDE Study, effectively ending the possibility that the direct renin inhibitor (DRI) Aliskiren will play a significant role in the management of patients with CKD already on an ACE or ARB. This development was disappointing but actually represents only part of a growing body of evidence that now casts ...Jan 17 -
No benefit of Aliskiren added on to ACE or ARB: a disappointing development
In a stunning development, Novartis said Tuesday that it will terminate the late-stage ALTITUDE study investigating Rasilez (aliskiren) in patients with type 2 diabetes and renal impairment on the recommendation of an independent data monitoring committee. The company indicated that the committee concluded that "patients were unlikely to benefi ...Dec 20 -
Generic drugs: a dangerous public misunderstanding?
Dr. Elizabeth Cohen, senior medical correspondent for CNN's Health, Medical and Wellness unit made a dangerously incorrect statement in her report on generic drugs in the US (Seen at approximately 1:37 of the following video). ...Jul 26 -
Bardoxolone in Chronic Kidney Disease: A major breakthrough?
In this week's New England Journal of Medicine, Pergola et al report the results of a phase 2 randomized trial of an antioxidant inflammation modulator, bardoxolone, in patients with type 2 diabetes and chronic kidney disease (CKD). Over a period of 52 weeks, 227 adults with CKD (defined as an estimated glomerular filtration rate [GFR] of 20 to ...Jul 03 -
Olmesartan delays the onset of microalbuminuria, but more deaths seen
The long awaited ROADMAP trial was recently published in the New England Journal of Medicine. This randomized controlled trial enrolled 4,447 patients to determine whether treatment with the angiotensin receptor blocker olmesartan could delay or prevent microalbuminuria. In the study, blood pressure was targeted at less than 130/80 mmHg, yet patien ...Mar 13 -
Other entries by Dr. Jordan Weinstein
Kenar Jhaveri
Kenar Jhaveri has not set their biography yet
Recent Posts
-
Novel Tools to Teach Nephrology
Nephrology has become a field of medicine that is vastly expanding in knowledge and complexity. The number of students, residents considering the field of nephrology are declining every year. Lot of times the students consider nephrology as a difficult subject to grasp and hence have a "renal fear" to consider this field of medicine. To make neph ...Jul 14 -
Other entries by Kenar Jhaveri